



ASX Release

Moffitt Cancer Center Doses First Patient in Phase 1b/2 Breast Trial

Melbourne, Australia - (26 September 2016) – Clinical-stage oncology company Prescient Therapeutics Limited (ASX: **PTX**) is pleased to announce that its novel drug candidate PTX-200 currently in a Phase 1b/2 trial for the treatment of locally advanced breast cancer at the Albert Einstein College of Medicine and Cancer Center in New York, has successfully dosed its first patient at the H. Lee Moffitt Cancer Center (**Moffitt**) in Florida.

PTX-200 is given in combination with chemotherapy agent paclitaxel as standard of care. The Phase 1b/2 trial is now in expansion phase enrollment at Albert Einstein College of Medicine and the Moffitt.

The Moffitt's principal investigator on the trial is Dr Heather Han, a medical oncologist specializing in breast cancer in The Centre for Women's Oncology at the brand new, state-of-the-art McKinley Campus at the Moffitt.

Dr Han said "I am delighted to be part of this exciting trial. PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many tumors, and contributes to paclitaxel resistance in breast cancer. I am so pleased that we have now dosed our first patient on this trial at the Moffitt. This first patient is so far responding well to treatment."

Each year, the Moffitt treats over 1,000 newly diagnosed breast cancer patients, as well as hundreds more who choose the Moffitt for treatment when they have a recurrence. Whilst only a fraction of these patients will meet the strict eligibility criteria of this clinical trial, including the type of breast cancer, PTX benefits not only from the large patient population but also from the Moffitt's multi-discipline expertise in breast cancer.

The Moffitt's Comprehensive Breast Program boasts a multispecialty, full-service clinic that offers the latest in preventive care and support for all breast-related conditions. Accordingly, breast cancer patients treated at the Moffitt have survival rates above the US national average.

ENDS

About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition through the ATP binding site, PTX-200 has a novel mechanism of action, through PH domain binding, that specifically inhibits Akt, with less likely side effects. This highly promising compound is now the focus of three current clinical trials.

The first trial, soon to commence, is a Phase Ib/II trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center (Yale) in New Haven, Connecticut under the leadership of Principal Investigator Professor Jeffrey Lancet, MD.



PTX is also conducting a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase Ib/II trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

Further enquiries:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440